UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE ROLE OF VITAMIN D STATUS ON EFFECTIVENESS OF BIOLOGIC THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Olivia Schütte 1, Lea Tessmer 2,3, Julia Stötzel 3, Oliver Schröder 2,3, Aysegül Aksan 1,3,4, Jürgen Stein 2,3,5

Affiliations

1 Justus-Liebig University Giessen, Giessen, Germany

2 DGD Clinics Sachsenhausen, Frankfurt am Main, Germany

3 Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, Germany

4 Immundiagnostik AG, Bensheim, Germany

5 Goethe University Frankfurt, Frankfurt am Main, Germany

Summary

AI Generated

A retrospective cohort study of 162 IBD patients found that maintaining sufficient vitamin D levels over time, rather than baseline vitamin D status, was associated with improved response to infliximab and ustekinumab treatment.

Higher vitamin D levels over time were associated with positive treatment response for patients on infliximab and ustekinumab (p<0.05), representing the first demonstration of this association for ustekinumab.
At baseline, 50.6% of patients were vitamin D deficient (≤30ng/mL) and 40.7% used vitamin D supplementation; baseline vitamin D status showed no conclusive relations with drug or anti-drug antibody levels.
Overall, 72.8% of patients responded to biologic treatment over one year; response was associated with biologic naivety (p=0.040), disease location in Crohn's disease (p=0.011), and lower inflammatory markers.
The authors conclude that regular vitamin D monitoring and long-term substitution in patients with low levels is indicated, as permanently sufficient levels rather than initial status were decisive for improved response.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

As well as having a major impact on bone metabolism, vitamin D (vitD) is recognised as an immunomodulatory hormone with a pivotal role in the pathogenesis of inflammatory bowel disease (IBD). Low vitD levels in patients with IBD are associated with active inflammation, disease severity, poor quality of life and adverse clinical outcomes. Furthermore, lower vitD levels in patients with IBD were shown to be associated with higher pro-inflammatory cytokine profiles. Therefore, it is plausible that vitD may have use as a therapeutic agent in IBD. Our previous work suggests that pre-treatment with vitD may improve effectiveness of biologic drugs such as TNF-α inhibitors and the anti-integrin agent vedolizumab (VDZ). However, data in this context is limited.

Aims & Methods

The aim of this study was to explore potential effects of serum vitD levels on biologic treatment response in IBD patients. A retrospective cohort study was conducted to monitor ambulant treatment of IBD patients with biologics in relationship to their vitD levels. Medical records and routine blood and stool samples of 162 adult IBD patients were assessed at therapy start and 8-weekly thereafter. Samples were analysed for standard blood count, total 25OHD, albumin and inflammation parameters (hsCRP, ESR and faecal calprotectin (FC)) by standard methods. Biologic treatments (infliximab (IFX), its biosimilars (IFX-s), VDZ and ustekinumab (UST)) were administered over 1 year. Drug and anti-drug antibody (ADA) levels were measured with systems provided by Immundiagnostik AG, Bensheim, Germany. VitD values were dichotomized into deficient (≤ 30ng/mL) and sufficient (>30ng/mL). A positive treatment response was defined according to evidence of inflammation as shown by change in hsCRP-levels from baseline to the last two samples monitored. IBM SPSS Statistics 24 was used for statistical analysis.

Results

162 patients with IBD (91 with Crohn’s disease (CD)/ 71 with ulcerative colitis (UC); 81 f/81 m; age 40.2±11.5y) were enrolled. At baseline, 40.7 % used vitD supplementation, 10.5 % were biologic naïve and 50.6 % were vitD deficient. No conclusive relations were found between baseline vitD or supplementation status with drug or ADA levels. However, higher vitD levels over time were associated with positive treatment response for patients on IFX and UST (p<0.05). Treatment specific analysis revealed no significant associations between drug TCs and overall vitD status or treatment response. In descriptive analysis, pre-treatment vitD status was not associated with demographic or clinical characteristics but positively associated with mean corpuscular volume (MCV) and FC and inversely related to transferrin. Ultimately, 72.8 % of patients responded to biologic treatment. Response was related to disease location in CD (p = 0.011) and positively associated with naivety to biologics (p = 0.040). Treatment responders had significantly higher Hb, iron, TSAT and significantly lower ESR, hsCRP and FC.

Conclusion

Our results support a protective role of vitD in IBD patients treated with the biologic agents IFX and UST, shown here for the first time for UST. Interestingly, not the initial vitD status, but permanently sufficient vitD levels were decisive for improved treatment response. Therefore, regular vitD monitoring and long-term vitD substitution in patients with low vitD levels is indicated.

Disclosure

Olivia Schütte, Lea Tessmer and Julia Stötzel have nothing to disclose. Aysegül Aksan is an employee of Immundiagnostik AG.
Oliver Schröder: Lecturing fees: Abbvie, Falk, Janssen, Takeda, Norgine and Pfizer. Congress expenses: Falk, Pfizer.
Jürgen Stein: Consulting: Abbvie, Bristol Myers Squibb, Dr Schär, Falk, Ferring, Fresenius Kabi, Immundiagnostik, Janssen, Medice, MSD, Pfizer, Pharmacosmos, Shire, Takeda, Thermofisher, Vifor. Board member: Abbvie, Bristol Myers Squibb, Dr Schär, Ferring, Fresenius Kabi, Immundiagnostik, Janssen, MSD, NPS, Pharmacosmos, Takeda, Vifor and Shield. Lecturing fees: Vifor Pharma

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Johannes R. Björk 1, Emily Oosterhout 1, Rose Leijdesdorff 1,2, Ranko Gacesa 1, Laura A. Bolte 1, Marjolein Anthonia Ymkje Klaassen 1, Geke A. P. Hospers 1, Rinse K. Weersma 1

Affiliations

1 University Medical Center Groningen, Groningen, Netherlands

2 Amsterdam University Medical Center, Amsterdam, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Lifestyle factors such as smoking, alcohol consumption, obesity, and diets rich in ultra-processed foods are established risk factors for cancer¹. The gut microbiome has recently been proposed as an additional hallmark of cancer², and previous studies have shown differences in gut microbiota between individuals with and without cancer³. Here, we investigated whether gut microbiota sampled prior to diagnosis is associated with future cancer risk.

Aims & Methods

We aimed to develop and evaluate a data-driven microbiome-based risk score for future cancer development using pre-diagnostic gut microbiota profiles. We analyzed 7,696 adult participants from the LifeLines Biobank with available stool metagenomic data from the Dutch Microbiome Project, linked to histologically confirmed cancer diagnoses in the Dutch Pathology Database. After excluding individuals with established (prevalent) cancer and pre-cancerous lesions at baseline, 245 participants were diagnosed with cancer during follow-up (minimum: 20 days; median: 7 years; maximum: 10 years), while 5,752 remained cancer-free.
We developed a microbiome-based classifier for overall cancer risk using presence-absence profiles of microbial species. Using 100-fold cross-validation, we derived a risk score comprising 28 species, which was evaluated in a multivariable Cox proportional hazard model adjusted for age, sex, BMI, smoking status (past/current), baseline disease status, diet and Bristol stool scale.

Results

In this cohort, the most common cancer types were breast (n = 58), gastrointestinal (n = 46), male reproductive (n = 45), and urinary tract cancers (n = 22), accounting for 70% of all incident cancers.
The multivariable Cox model showed that the microbiome risk score was associated with incident cancer (HR = 1.60, SE = 0.06; P < 0.001), along with age (HR = 1.06, SE = 0.01; P < 0.001) and smoking (HR = 1.29, SE = 0.02; P = 0.051). The cancer types with the largest risk scores included respiratory, skin, male reproductive, and gastrointestinal cancers. In external data, the risk score also distinguished prevalent cancer from cancer-free controls (P < 0.001).

Conclusion

In a population-based cohort with long follow-up time, a data-driven microbiome-based risk score was associated with subsequent cancer risk and distinguished established cancer in external data, suggesting that gut microbial composition reflects host states linked to cancer susceptibility.

References

Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008 Sep; 25(9): 2097-116. doi: 10.1007/s11095-008-9661-9.
Douglas Hanahan; Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 Jan; 12 (1): 31–46. doi: 10.1158/2159-8290.CD-21-1059
Thomas, A.M., Fidelle, M., Routy, B. et al. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol 20, 583–603 (2023). https://doi.org/10.1038/s41571-023-00785-8

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine Stomach & H. Pylori Digestive Oncology Oesophagus

Submission format

Abstract

Session

Evolving molecular paradigms in gastric cancer

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

meiling zhou 1, Jing Ning 1, Xin Guan 1, Jing2 Zhang 1, Shigang Ding 1

Affiliations

1 Peking University Third Hospital, Beijing, China

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Helicobacter pylori drives gastric mucosal injury and gastric carcinogenesis through complex interactions between bacterial virulence factors and host epithelial cells. While CagA has been extensively studied, additional bacterial effectors likely contribute to disease pathogenesis. Our preliminary findings identified H. pylori thioredoxin 1 (Trx1) as a potential host-interacting effector.

Aims & Methods

This study aimed to investigate the pathogenic role of Trx1 and its underlying mechanism in gastric epithelial cells. Recombinant H. pylori Trx1 was expressed in Escherichia coli, purified by nickel-affinity chromatography and gel filtration, and functionally validated by insulin reduction assay. Gastric epithelial cells were treated with recombinant Trx1 to assess proliferative responses by CCK-8 assay and Ki-67 immunofluorescence, and intracellular localisation by immunofluorescence microscopy. Candidate host-binding proteins were identified by pull-down coupled with liquid chromatography-tandem mass spectrometry. Transcriptomic profiling was performed to identify downstream signalling pathways, followed by RT-qPCR and western blot validation. The interaction between Trx1 and EPHA2 was further evaluated by immunofluorescence colocalisation and surface plasmon resonance (SPR). EPHA2 overexpressed and knockout models were used to determine its role in Trx1-induced signalling.

Results

Recombinant Trx1 was successfully expressed and purified, and retained enzymatic activity in the insulin reduction assay. Trx1 significantly enhanced proliferative activity in gastric epithelial cells, as shown by increased CCK-8 growth signals and increased Ki-67 fluorescence intensity after 48 h of treatment (P < 0.05). Importantly, these findings were reproduced in gastric organoids, where Trx1 increased organoid growth. Immunofluorescence showed that Trx1 was localised to the cell membrane and cytoplasm. Pull-down coupled with mass spectrometry identified EPHA2 as a candidate host-binding protein. This interaction was confirmed by immunofluorescence colocalisation and SPR, which demonstrated direct binding between Trx1 and the EPHA2 extracellular domain with a dissociation constant (KD) of 2.41 × 10⁻⁷ M. Transcriptomic analysis revealed significant enrichment of the PI3K/AKT/NF-κB pathway. RT-qPCR showed that IL8, ICAM1 and VCAM1 were significantly upregulated (all P < 0.05). Trx1 induced EPHA2 phosphorylation, which peaked at 30 min to 1 h, while downstream p-AKT and p-p65 were activated from 1 h and remained significantly elevated at 2, 6, 12 and 24 h. EPHA2 knockout or pharmacological inhibition of PI3K attenuated Trx1-induced proliferative and inflammatory responses, supporting a central role for the EPHA2-PI3K/AKT-NF-κB axis.

Conclusion

H. pylori Trx1 directly binds EPHA2 and activates proliferative and inflammatory signalling in gastric epithelial cells. These findings identify Trx1 as a previously underappreciated host-interacting effector of H. pylori and provide a mechanistic basis for its contribution to gastric mucosal injury.

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Stomach & H. Pylori Mechanisms & Personalised Medicine Immunology Oesophagus

Submission format

Abstract

Session

Mapping molecular interactions in the upper gastrointestinal tract

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Surgery’s invisible enemy: Outsmarting infections before they start

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda 1

Affiliations

1 Queen Elizabeth University Hospital, Glasgow, United Kingdom

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Barcelona 2026

Topics

Surgery Standards & Guidelines Oesophagus Colorectal

Session

From guidelines to clinical practice: Digestive guidelines unplugged – what’s new, what’s next?

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Oleksandr Babii 1, Natalia Prolom 1, Serhii Tarabarov 1, Marina Titova 1

Affiliations

1 SI “Institute of Gastroenterology of the National Academy of Medical Sciences of Ukraine”, Dnipro, Ukraine

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

The main goal in treating esophageal achalasia (EA) is to facilitate the patency of the esophagogastric junction (EGJ). Among the current treatment options for EA, pneumatic balloon dilation (BD) is the most common method because it is simple to perform, minimally invasive, and does not require special training. Because recurrence after BD is common, peroral endoscopic myotomy (POEM) has been increasingly adopted. However, clear indications for the use of EA treatment methods have not been definitively determined.

Aims & Methods

The aim of this study was to determine the indications for a differentiated approach to the treatment of EA.
From January 2023 to December 2025, 31 patients diagnosed with EA were evaluated and treated in the digestive system surgery department. High resolution manometry (HRM) classified patients as type I (n=12), type II (n=16), and type III (n=3). The cohort included 12 men (38.7%) and 19 women (61.3%) aged 28 to 74 (40.2 ± 5.4) years. The Eckardt score was used for clinical assessment of EA symptoms. Fluoroscopy was used to determine the diameter of the esophagus, evacuation rate, and length of EGJ narrowing. Endoscopy assessed retained esophageal contents and resistance to passage through the lower esophageal sphincter (LES). EUS with compression elastography was used to determine the structure of the wall of the distal third of the esophagus and LES: a green–yellow pattern indicated hypertrophy, whereas a blue pattern indicated fibrosis. As the first stage of treatment, all patients underwent pneumatic balloon dilation (BD) with balloon systems with a diameter of 35 mm.

Results

After a course of BD (2-5 sessions lasting 60-180 sec) according to the Eckardt score, the symptomatic effectiveness of treatment was 87.1%; the effectiveness of LES relaxation during HRM was 83.8%; the increase in contrast evacuation rate during fluoroscopy was 77.4% after the first course and 80.6% after the repeat BD course. Regardless of the type of EA, the pressure in the LES did not differ (p>0.05), but it decreased significantly (p<0.05) after the BD course. In 2 (6.5%) cases, there were post-dilatation complications: submucosal haematoma and longitudinal tears of the mucous membrane of the distal third of the esophagus. During the follow-up period of up to 16 months, EA recurrence after the first course of BD was observed in 22.6% of cases: type I – 2 (6.5%), type II – 4 (12.9%), type III – 1 (3.2%). In 19.4% of cases of EA recurrence, repeated courses of BD were ineffective. To determine the causes of recurrence in these patients, EUS was performed and fibrosis with thickening of the wall of the distal third of the esophagus – 3.26 (3.12; 3.38) mm and LES – 5.65 (5.14; 6.14) mm was diagnosed. The presence of fibrosis contributed to post-dilatation complications and EA recurrence. In 19.4% of cases of EA recurrence following BD, POEM was performed. According to the Eckardt score, symptomatic treatment efficacy and increased contrast evacuation rate during fluoroscopy at follow-up periods up to 12 months were observed in 5 out of 6 patients.

Conclusion

EA recurrence is associated with fibrotic transformation of the wall of the distal third of the esophagus and LES. The use of HRM allows assessing the effectiveness of BD. EUS enables differentiation between hypertrophy and fibrotic transformation of the distal esophageal wall and the LES; the latter may warrant myotomy.

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine Surgery Neurogastroenterology & Motility Endoscopy Oesophagus

Submission format

Abstract

Session

Achalasia: Beyond the bird's beak - Tailoring therapy to the patient

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin 1

Affiliations

1 Centre Hépato-Biliaire Paul Brousse, Villejuif, France

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Topics

Surgery Radiology & Imaging Immunology Hepatobiliary

Session

Avoid inflammation and intoxication: Management of autoimmune and alcohol-related liver disease

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Vincent Bos 1, Lisanne Pattynama 1, Annick van Nunen 2, Wouter L. Curvers 3, Yasmijn van Herwaarden 4, Pieter Jan de Jonge 5, Jolanda van Dieren 6, Akin Inderson 7, Daan De Koning 8, Robert Laheij 9, peter oosterwijk 10, K. Soufidi 2, Grard A. P. Nieuwenhuijzen 3, Merlijn Hutteman 4, Johanna van Sandick 6, Kirill Basiliya 7, Nina Beekmans 8, Eric Belgers 2, Wietse J. Eshuis 1, Roos E. Pouw 11

Affiliations

1 Amsterdam UMC, Amsterdam, Netherlands

2 Zuyderland Medical Center, Sittard-Geleen, Netherlands

3 Catharina Hospital, Eindhoven, Netherlands

4 Radboud University Medical Center, Nijmegen, Netherlands

5 Erasmus MC, Rotterdam, Netherlands

6 the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

7 Leiden University Medical Center, Leiden, Netherlands

8 Gelre Hospitals, Apeldoorn, Netherlands

9 Elisabeth-Tweesteden Hospital, Tilburg, Netherlands

10 Hospital Group Twente, Almelo, Netherlands

11 UMC Utrecht, Utrecht, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Transmural defects of the upper gastrointestinal (GI) tract can occur due to anastomotic leakage (AL), iatrogenic perforations, and non-iatrogenic perforations, such as Boerhaave syndrome. Upper-GI defects are associated with high morbidity and mortality. Treatment strategies include conservative therapy, endoscopic stenting, percutaneous drainage, surgery, and endoscopic vacuum therapy (EVT). EVT is a relatively novel technique that involves applying negative pressure therapy within the upper-GI lumen or in the cavity behind the defect, often using a vacuum-sponge or vacuum-stent. With a reported success rate of 80-100%, EVT is promising, however, prospective data are scarce, and strategies are not yet standardized or optimized.

Aims & Methods

In this prospective multicenter registry study in 12 hospitals in the Netherlands, we aimed to report the safety and efficacy of EVT for upper-GI transmural defects, to further optimize treatment strategies. All patients (aged ≥ 18 years) treated with EVT ± additional therapy for transmural upper-GI defects between January 2023 - February 2026 were eligible. EVT was performed according to local protocols. The primary outcome was successful EVT, defined as defect closure by EVT. Secondary outcomes included parameters on diagnosis, EVT treatment, additional interventions, and follow-up.

Results

In total, 221 patients (median age 66 years (IQR 58-73), 145 (66%) male) were included. The majority were treated for anastomotic leakage after surgery for malignancy (142/221; 64%) or benign indications (25/221; 11%), followed by iatrogenic defects (33/221; 15%), Boerhaave syndrome (12/221; 5%), other non-iatrogenic defects 9/221; 4%). Defects were detected after a median of 6 days (IQR 3-10). CT scan or contrast swallow examinations were performed in 207/221 (94%) patients and showed contrast leakage in 48%, fluid collections in 37%, and pneumothorax requiring drainage in 14%. An extraluminal cavity was present during endoscopy in 64/221 (29%) patients, which was endoscopically accessible in 42/64 (66%).
EVT was started a median of 1 days (IQR 0-1) after diagnosis of the defect, with a VacStent in 57% or an EsoSponge in 43% as initial EVT. Eventually, 29% patients underwent treatment with EsoSponge only, 47% with VacStent only, and 23% with a combination of EsoSponge and VacStent. Defects were successfully closed in 77% after a median of 16 days (IQR 8-26) and of 4 EVT-related endoscopies (3-6).
EVT failed because closure was not achieved (15%), due to death during treatment (5%), iatrogenic defect expansion of a post-transesophageal echocardiography defect beyond the limits of EVT, resulting in death in one patient who was unfit for surgical rescue (0.5%), or other reasons (2%). EVT-related adverse events (AGREE classification ≥3) occurred in 7%. Patients in whom EVT failed were significantly older (p=.004), were more often treated for non-AL defects (p=.003), had higher perforation severity scores (p<.001), and had a higher number of collections requiring additional percutaneous drainage (p=.015).

Total N = 221	Age (yrs), median (IQR)	CRP (10⁹/L), median (IQR)	Cavity at endoscopy (yes), n (%)	Defect size (mm), median (IQR)	Sponge treatment only, n (%) / success % / EVT duration (days), median (IQR)	VacStent treatment only, n (%) / success % / EVT duration (days), median (IQR)	Sponge+VacStent treatment, n (%) / success % / EVT duration (days), median (IQR)
AL oncologic surgery (n=142)	67 (60-73)	226 (157-310)	39 (27)	3 (0-15)	51 (36) / 76 / 16 (8-28)	55 (39) / 93 / 14 (8-23)	33 (23) / 61 / 27 (19-50)
AL benign surgery (n=25)	53 (45-62)	188 (100-380)	5 (20)	10 (0-10)	3 (12) / 100 / 13 (N/A)	16 (64) / 100 / 15 (7-21)	6 (24) / 83 / 20 (15-52)
Iatrogenic (n=33)	69 (43-76)	140 (16-215)	12 (36)	10 (9-20)	10 (30) / 60 / 11 (6-21)	15 (46) / 73 / 13 (7-15)	8 (24) / 63 / 30 (12-43)
Boerhaave syndrome (n=12)	63 (56-76)	55 (3-223)	7 (58)	30 (20-40)	-	10 (83) / 60 / 10 (7-27)	2 (17) / 50 / 32 (N/A)
Other non-iatrogenic (n=9)	67 (59-73)	137 (52-258)	1 (11)	5 (2-19)	1 (11) / 100 / 12 (N/A)	7 (78) / 57 / 7 (5-15)	1 (11) / 0 / 10 (N/A)
AL: anastomotic leakage; EVT: endoscopic vacuum therapy; IQR: interquartile range; mm: millimeters; N/A: not applicable; yrs: years

Conclusion

This is the largest prospective EVT cohort to date. Results show high closure rates (77%) and few adverse events (7%).

Event

UEG Week Barcelona 2026

Topics

Oesophagus Histopathology Endoscopy Digestive Oncology

Submission format

Abstract

Session

Interventional endoscopy: What's new and cool!

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

A GUT MICROBIOME-DERIVED RISK SCORE IS ASSOCIATED WITH FUTURE CANCER DIAGNOSIS IN A DUTCH POPULATION-BASED COHORT

Rinse K. Weersma

HELICOBACTER PYLORI THIOREDOXIN 1 DIRECTLY ENGAGES EPHA2 TO PROMOTE PROLIFERATIVE AND INFLAMMATORY SIGNALLING IN GASTRIC EPITHELIAL CELLS

Shigang Ding

Surgery’s invisible enemy: Outsmarting infections before they start

Yasuko Maeda

A DIFFERENTIATED APPROACH TO SELECTING THE ENDOSCOPIC SURGICAL TECHNIQUE FOR THE TREATMENT OF ESOPHAGEAL ACHALASIA

Marina Titova

Optimised management of severe acute autoimmune hepatitis: What is the best timing for liver transplantation?

Eleonora De Martin

HIGH SUCCESS RATES AFTER ENDOSCOPIC VACUUM THERAPY FOR UPPER GI TRANSMURAL DEFECTS: FIRST RESULTS FROM THE DUTCH PROSPECTIVE EVT REGISTRY

Roos E. Pouw